Note: The drugs below for erectile dysfunction are classified as, BLACK for circumstances outside of those listed below, where prescribing on the NHS is not permitted (except for generic sildenafil only).
They are classified as RED where prescribed for severe distress on the NHS by a specialist service– all prescribing for severe distress must remain with the specialist and not transferred to the general practitioner (except for generic sildenafil only).
The Pan Mersey Area Prescribing committee recommends generic sildenafil as the phosphodiesterase type-5 inhibitor of choice for the treatment of erectile dysfunction.
Treatment for erectile dysfunction on the NHS is limited to those men suffering with erectile dysfunction with any of the following conditions (except for generic sildenafil where these restrictions do not apply):
> have diabetes, multiple sclerosis, Parkinson’s disease, poliomyelitis, prostate cancer, severe pelvic injury, single gene neurological disease, spina bifida, or spinal cord injury;
> are receiving dialysis for renal failure;
> have had radical pelvic surgery, prostatectomy (including transurethral resection of the prostate), or kidney transplant;
> were receiving Caverject®, Erecnos®, MUSE®, Viagra®, or Viridal® at the expense of the NHS on 14 September 1998
> are suffering severe distress as a result of impotence using the following criteria, and prescribed from specialist services, considering the following criteria:
o significant disruption to normal social and occupational activities
o a marked effect on mood, behaviour, social and environmental awareness
o a marked effect on interpersonal relationships
The Department of Health advises that one treatment a week will be appropriate for most patients treated for erectile dysfunction.
The Pan Mersey Area Prescribing Committee does not currently recommend prescribing of daily tadalafil tablets 5mg (Cialis®) for the treatment of benign prostatic hyperplasia (BPH).
Potassium aminobenzoate has been used in the treatment of various disorders associated with excessive fibrosis such as Peyronie's disease. There is some evidence to support efficacy in reducing progression of Peyronie's disease when given early in the disease. However there is no evidence for reversal of the condition.